A Year of Growth and Milestones: VIVEbiotech 2025
From strategic investment to industry recognition and our 10-year anniversary, 2025 has marked a pivotal chapter in VIVEbiotech’s journey.
As 2025 comes to an end, VIVEbiotech looks back on a year defined by progress, recognition, and strategic advancement in lentiviral vector development and manufacturing.
The year began with renewed momentum following the growth investment from Ampersand Capital Partners in late 2024. This partnership reinforced the company’s long-term vision to strengthen its ability to scale and expand its services to support global cell and gene therapy programs.
Soon after, the company received one of the industry’s most meaningful recognitions: the CMO/CDMO of the Year Award from Phacilitate, presented in Dallas. This milestone highlighted the expertise, dedication, and commitment of the VIVEbiotech team.
In March, VIVEbiotech celebrated its 10th anniversary as a CDMO exclusively dedicated to lentiviral vector development and manufacturing. Over the past decade, the company has supported partners worldwide in advancing transformative cell and gene therapy programs. Every vector produced represents a step towards meaningful scientific and clinical impact.
Looking ahead, VIVEbiotech continues moving forward with its expansion plans, preparing for a new phase of growth that will further increase capacity and strengthen its offering.
As the year concludes, VIVEbiotech extends its appreciation to employees, collaborators, and partners for their trust and support throughout 2025.
To watch the full video recap, click here.
VIVEbiotech wishes everyone a wonderful holiday season and a successful start to 2026.